Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
公司代码FLGT
公司名称Fulgent Genetics Inc
上市日期Sep 28, 2016
CEOHsieh (Ming)
员工数量1313
证券类型Ordinary Share
年结日Sep 28
公司地址4399 Santa Anita Ave
城市EL MONTE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编91731
电话16263500537
网址https://www.fulgentgenetics.com/
公司代码FLGT
上市日期Sep 28, 2016
CEOHsieh (Ming)